Mayne's growth strategy is set to deliver
Mayne Pharma remains one of the most sought-after growth stocks on the ASX and a stronger US dollar will help further.
Mayne Pharma remains one of the most sought-after growth stocks on the ASX and a stronger US dollar will help further.
Fund manager Artisan's Mike Schneider finds technologies that are on the cusp of new applications or geographies.
US stocks rose as August payroll data signalled steady jobs growth, tempering bets on a rate lift.
Low bond yields have been providing an artificial boost to cash flow-based valuations for years.
Investor fears of an imminent US rate rise and falling commodity prices triggered a hefty selloff that saw the ASX end the week in the red.
Brokers Evans and Partners and Bell Potter Securities were seeking bids for 16.9 million shares in listed printing company IVE Group on Frid...
Global equities manager Antipodes Partners has turned its attention to hitting $330 million for its new listed investment company, after cru...
Macquarie's equities desk was in the market with 53 million shares in Macquarie Atlas Roads Group on Friday morning.
Brokers First NZ Capital and Macquarie Capital have ramped up marketing for New Zealand King Salmon's planned initial public offering, intro...
Top fund managers discuss their standout stock pick for the year ahead.
Unlimited access to business news and market insights across any device
Already a subscriber? Log in